Replies to post #238557 on Biotech Values

[willyw]

I'm wondering if I'm following.
There is new data on a new compound (I think) ATI-2173,
which to me looks good (note: Phase 1b results w/ 24 subjects?)
https://www.natap.org/2021/EASL/EASL_45.htm

So then the question would be will the triple therapy be effective?
It looks potentially so to me.
Note that ATI-2173 is different than ABI-H0731 (I believe).

(In 5 days ABUS has only fallen in value since EASL or the collaborative announcement, so it doesn't appear the market is enthused.)